Cover Image
市場調查報告書

肺動脈性高血壓 : 開發平台分析

Pulmonary Arterial Hypertension - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213126
出版日期 內容資訊 英文 214 Pages
訂單完成後即時交付
價格
Back to Top
肺動脈性高血壓 : 開發平台分析 Pulmonary Arterial Hypertension - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 214 Pages
簡介

所謂肺動脈性高血壓,是肺動脈(心臟到肺,輸送帶氧氣血液的動脈)內部血壓上升這樣的疾病。主要的症狀為倦怠感和暈眩,昏厥,胸部壓迫感、疼痛,腳踝、腿部的腫脹(浮腫),呼吸急促(呼吸困難)等。主要的治療藥有抗凝結劑和利尿劑、血管擴張藥等。

本報告提供全球各國治療肺動脈高血壓(PAH)用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

肺動脈性高血壓概要

治療藥的開發

  • 肺動脈性高血壓開發中產品:概要
  • 肺動脈性高血壓開發中產品:比較分析

各企業開發中的肺動脈性高血壓治療藥

大學/研究機關研究中的肺動脈性高血壓治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

肺動脈性高血壓治療藥:開發中的產品的一覽(各企業)

肺動脈性高血壓治療藥:研究中的產品的一覽(大學/研究機關別)

肺動脈性高血壓治療藥的開發企業

  • APT Therapeutics, Inc.
  • Arena Pharmaceuticals, Inc.
  • 旭化成製藥
  • Ascendis Pharma A/S
  • Bial - Portela & Ca, S.A.
  • Cardioxyl Pharmaceuticals, Inc.
  • Carolus Therapeutics, Inc.
  • Celsion Corporation
  • Corridor Pharmaceuticals Inc.
  • Cytokinetics, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Insmed Incorporated
  • Lacer, S.A.
  • LTT Bio-Pharma Co., Ltd.
  • Mezzion Pharma Co. Ltd.
  • miRagen Therapeutics, Inc.
  • 日本新藥
  • Novartis AG
  • Peloton Therapeutics, Inc.
  • PharmaIN Corporation
  • PhaseBio Pharmaceuticals, Inc.
  • Pluristem Therapeutics Inc.
  • Proteo, Inc.
  • Pulmokine, Inc.
  • Reata Pharmaceuticals, Inc.
  • Respira Therapeutics, Inc.
  • Sagene Pharmaceuticals, Inc.
  • Silence Therapeutics Plc
  • Sinoxa Pharma GmbH
  • SteadyMed Therapeutics, Inc.
  • Suda Ltd
  • Toray Industries

肺動脈性高血壓:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (allopurinol + apocynin)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 癌症·肺動脈性高血壓(PAH)抗體
  • 肺動脈性高血壓抗體
  • APT-102
  • bardoxolone methyl
  • beraprost sodium ER
  • beraprost sodium SR
  • BIA-51058
  • CT-2009
  • 肺動脈性高血壓觸點3受體拮抗劑
  • fasudil
  • GS-4997
  • imatinib mesylate
  • INS-1009
  • LA-419
  • Lisuride
  • MFC-001
  • MFC-002
  • 肺動脈性高血壓 Endothelin-1抑制用寡核甘酸
  • 肺動脈性高血壓MicroRNA-145抑制用寡核甘酸
  • 肺動脈性高血壓miR-145抑制用寡核甘酸
  • PB-1046
  • PB-1120
  • 肺動脈性高血壓Urotensin-II受體較量胜肽
  • PGC-VIP
  • PK-10453
  • PK-10571
  • PLX-PAD
  • PT-2977
  • QCC-374
  • R-190
  • ralinepag
  • RT-234
  • selegiline+PDE-5抑制劑
  • selexipag
  • 肺動脈性高血壓小分子
  • 血管功能障礙·肺動脈性高血壓·勃起障礙aruginaze抑制劑
  • 慢性阻塞性肺病(COPD)·氣喘·肺動脈性高血壓肌凝蛋白抑制用小分子
  • 肺動脈性高血壓可容性環氧樹脂do水解?抑制劑
  • 肺動脈性高血壓ACE2活躍用小分子
  • 肺動脈性高血壓5-HT1B工作小分子
  • SPI-054
  • SPI-183
  • SUD-004
  • Tacrolimus
  • tadarafiru
  • tiprelestat
  • TPN-171
  • TR-422
  • treprostinil
  • treprostinil diolamine
  • TXA-127
  • udenafil

肺動脈性高血壓治療藥:開發中產品的最新趨勢

肺動脈性高血壓治療藥:暫停開發的產品

肺動脈性高血壓治療藥:中止開發的產品

肺動脈性高血壓相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8450IDB

Summary

Global Markets Direct's, 'Pulmonary Arterial Hypertension - Pipeline Review, H2 2016', provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
  • The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pulmonary Arterial Hypertension Overview
  • Therapeutics Development
    • Pipeline Products for Pulmonary Arterial Hypertension - Overview
    • Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis
  • Pulmonary Arterial Hypertension - Therapeutics under Development by Companies
  • Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes
  • Pulmonary Arterial Hypertension - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Pulmonary Arterial Hypertension - Products under Development by Companies
  • Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes
  • Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • APT Therapeutics, Inc.
    • Arena Pharmaceuticals, Inc.
    • Ascendis Pharma A/S
    • AVEO Pharmaceuticals, Inc.
    • Bial - Portela & Ca, S.A.
    • Celsion Corporation
    • Celtaxsys, Inc.
    • Chugai Pharmaceutical Co., Ltd.
    • Complexa, Inc.
    • Eli Lilly and Company
    • Galectin Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • HitGen LTD
    • Insmed Incorporated
    • INVENT Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Kowa Company, Ltd.
    • Mast Therapeutics, Inc.
    • Mezzion Pharma Co. Ltd.
    • miRagen Therapeutics, Inc.
    • Morphogen-IX Limited
    • Nippon Kayaku Co., Ltd.
    • Nippon Shinyaku Co., Ltd.
    • Novartis AG
    • Peloton Therapeutics, Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • Pluristem Therapeutics Inc.
    • Proteo, Inc.
    • Pulmokine, Inc.
    • Reata Pharmaceuticals, Inc.
    • Respira Therapeutics, Inc.
    • Reviva Pharmaceuticals Inc.
    • Selten Pharma, Inc
    • Silence Therapeutics Plc
    • SteadyMed Therapeutics, Inc.
    • Suda Ltd
    • Toray Industries, Inc.
  • Pulmonary Arterial Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acebilustat - Drug Profile
    • Antibody for Pulmonary Arterial Hypertension - Drug Profile
    • Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile
    • APT-602 - Drug Profile
    • AV-353 - Drug Profile
    • bardoxolone methyl - Drug Profile
    • beraprost sodium ER - Drug Profile
    • beraprost sodium SR - Drug Profile
    • BIA-51058 - Drug Profile
    • BMP-10 - Drug Profile
    • BMP-9 - Drug Profile
    • CTX-3397 - Drug Profile
    • CXA-10 - Drug Profile
    • Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile
    • GMA-301 - Drug Profile
    • GMCT-01 - Drug Profile
    • GRMD-02 - Drug Profile
    • HGP-1207 - Drug Profile
    • INS-1009 - Drug Profile
    • INV-240 - Drug Profile
    • JNJ-26993135 - Drug Profile
    • KAR-5585 - Drug Profile
    • macitentan - Drug Profile
    • MFC-1040 - Drug Profile
    • MFC-2040 - Drug Profile
    • Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile
    • Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile
    • PB-1046 - Drug Profile
    • PB-1120 - Drug Profile
    • PF-543 - Drug Profile
    • pitavastatin NP - Drug Profile
    • PK-10453 - Drug Profile
    • PK-10571 - Drug Profile
    • PLX-PAD - Drug Profile
    • PT-2977 - Drug Profile
    • QCC-374 - Drug Profile
    • R-190 - Drug Profile
    • ralinepag - Drug Profile
    • RP-5063 - Drug Profile
    • RT-234 - Drug Profile
    • selexipag - Drug Profile
    • selonsertib - Drug Profile
    • sirolimus albumin-bound - Drug Profile
    • Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile
    • Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile
    • Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile
    • Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile
    • Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile
    • sodium nitrite - Drug Profile
    • SPI-054 - Drug Profile
    • SPI-183 - Drug Profile
    • SUD-004 - Drug Profile
    • Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile
    • tacrolimus - Drug Profile
    • tadalafil - Drug Profile
    • tiprelestat - Drug Profile
    • tocilizumab - Drug Profile
    • TR-422 - Drug Profile
    • treprostinil - Drug Profile
    • treprostinil diolamine - Drug Profile
    • ubenimex - Drug Profile
    • udenafil - Drug Profile
  • Pulmonary Arterial Hypertension - Dormant Projects
  • Pulmonary Arterial Hypertension - Discontinued Products
  • Pulmonary Arterial Hypertension - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016
  • Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Celtaxsys, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Complexa, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Kowa Company, Ltd., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Limited, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Pulmokine, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Selten Pharma, Inc, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2016
  • Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pulmonary Arterial Hypertension - Dormant Projects, H2 2016
  • Pulmonary Arterial Hypertension - Dormant Projects (Contd..1), H2 2016
  • Pulmonary Arterial Hypertension - Dormant Projects (Contd..2), H2 2016
  • Pulmonary Arterial Hypertension - Dormant Projects (Contd..3), H2 2016
  • Pulmonary Arterial Hypertension - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016
  • Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top